The Artificial Heart: Prototypes, Policies, and Patients
Committee to Evaluate the Artificial Heart Program of the National Heart, Lung, and Blood Institute, Division of Health Care Services, Institute of Medicine
National Academies Press, Jan 15, 1991 - Medical - 286 pages
A significant medical event is expected in 1992: the first human use of a fully implantable, long-term cardiac assist device. This timely volume reviews the artificial heart program--and in particular, the National Institutes of Health's major investment--raising important questions.
The volume includes:
What people are saying - Write a review
We haven't found any reviews in the usual places.
Current Status and History
Technological Potential and Research and Development Costs
3 Decisions for Future Research and Development
4 Clinical Effectiveness and Need For LongTerm Circulatory Support
5 Quality of Life and Mechanical Circulatory Support Systems
6 CostEffectiveness Analysis
7 The Appropriate Use of Technology
Other editions - View all
ABIOMED allocation alternative application appropriate artificial heart program Barney Clark benefits biomedical engineering Blood Institute blood pump C/E ratio cardiac cardiovascular circulatory support devices CIRCULATORY SUPPORT SYSTEMS clinical effectiveness clinical trials committee committee's comorbidities complications congestive heart failure considerations considered conventional medical cost cost-effectiveness analysis coverage criteria death decisions donor heart end-stage heart disease estimates ethical evaluation factors federal fully implantable function funding health-related quality heart failure heart transplantation hemolysis hospital impact important improve Institute of Medicine left ventricular assist levels long-term MCSSs Lung MCSS development MECHANICAL CIRCULATORY SUPPORT Medicare National Academy Press National Heart NHLBI Novacor outcomes patients percent potential QALY quality-adjusted quality-of-life rates recommends registry research and development Scenario short-term specific TAH development therapy third-party payers thromboembolic total artificial heart treatment utilized VADs valves ventricular assist device